Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales
ALLO's Q3 loss narrows to 19 cents per share, beating estimates, as R&D and G&A costs decline despite no product sales.
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
Tvardi Therapeutics' shares crater after its phase II idiopathic pulmonary fibrosis study shows no meaningful benefit from TTI-101 therapy compared to placebo.
Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain
ZTS secures CVMP's positive opinion recommending the approval of Lenivia, a long-acting OA pain therapy for dogs, with the final decision expected in late 2025.
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder
Teva secures FDA approval for Uzedy label expansion to treat adults with bipolar I disorder.
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza
Cidara Therapeutics wins FDA Breakthrough Therapy tag for CD388 for the prevention of seasonal influenza. Stock rises.
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
Ovid Therapeutics jumps 39% in a month after phase I epilepsy study data show superior efficacy of its lead candidate, OV329, hinting at best-in-class potential.
This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Allogene Therapeutics ( NASDAQ:ALLO ) , Akero Therapeutics ( NASDAQ:AKRO )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. HC Wainwright & Co. analyst Andrew S.
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure
KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study
AZN's baxdrostat hit the main goal in the phase III Bax24 study, showing significant blood pressure reductions in patients with resistant hypertension.
MRK Expands Tulisokibart Program in Three New Inflammatory Diseases
Merck broadens its tulisokibart clinical program with three new phase IIb studies, deepening its reach across immune-mediated inflammatory diseases.
Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update
KRYS shares jump after the FDA expands Vyjuvek's label to include DEB patients from birth, with added at-home use flexibility.
Why Is Allogene Therapeutics ( ALLO ) Up 9.4% Since Last Earnings Report?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investing in Oncology: 3 Cancer Stocks With Promising Pipelines
Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.
AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA
Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia
Agios shares tank as the FDA extends the review period for Pyrukynd in thalassemia by three months, pushing the final ruling to Dec. 7, 2025.
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
ALLO posts a narrower second-quarter 2025 loss. The company advances multiple CAR T programs targeting cancer and autoimmune diseases.
Allogene Q2 Cash Tops $300 Million
Allogene Therapeutics ( NASDAQ:ALLO ) reported second-quarter 2025 results on August 13, 2025, highlighting $302.6 million in cash and investments as of the end of Q2 2025 with a projected cash runway into the second half of 2027 despite reporting a GAAP net loss of $50.9 million.
Allogene Narrows Loss in Fiscal Q2
Allogene Therapeutics ( NASDAQ:ALLO ) , a biotechnology company developing off-the-shelf cell therapies for cancer and autoimmune diseases, reported its second quarter 2025 results on August 13, 2025. The release highlighted a smaller-than-expected GAAP net loss for Q2 2025. as the company ...
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update - Allogene Therapeutics ( NASDAQ:ALLO )
Conference Call and Webcast Scheduled for August 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc.
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc. ( Nasdaq: ALLO ) , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ( AlloCAR T™ ) products for cancer and autoimmune disease, today announced that it will report the ...
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates
NEW YORK, Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Cellectis ( the "Company" ) ( Euronext Growth: ALCLS - NASDAQ: CLLS ) , a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided financial results for the second ...
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday - Allogene Therapeutics ( NASDAQ:ALLO ) , AvalonBay Communities ( NYSE:AVB )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. JP Morgan analyst Brian Cheng downgraded the rating for Allogene Therapeutics, Inc.
Allogene Resets Clinical Course After Patient Death In Lymphoma Study - Allogene Therapeutics ( NASDAQ:ALLO )
Allogene halts the ALLO-647 arm in the ALPHA3 trial after a patient's death is linked to a viral infection. Cema-cel will now be evaluated with standard FC only; next data due in first half of 2026. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide ( FC ) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel ( Cema-Cel ) in First-Line Consolidation for Large B-Cell Lymphoma
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc. ( Nasdaq: ALLO ) , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ( AlloCAR T™ ) products for cancer and autoimmune disease, today announced that it has selected ...
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.
CAR T-Cell Therapy Market to Surge at 40.2% CAGR Over the Next Five Years
Boston, July 10, 2025 ( GLOBE NEWSWIRE ) -- According to the latest study from BCC Research, the "Current R&D Status of Chimeric Antigen Receptor ( CAR ) T-Cell Therapy Market" is expected to grow from $4.6 billion in 2024 to $25.1 billion by the end of 2029, at a compound annual growth rate ( ...
Why Is Allogene Therapeutics ( ALLO ) Up 52.2% Since Last Earnings Report?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
All You Need to Know About Allogene Therapeutics ( ALLO ) Rating Upgrade to Buy
Allogene Therapeutics (ALLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
SOUTH SAN FRANCISCO, Calif., June 01, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc. ( Nasdaq: ALLO ) , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ( AlloCAR T™ ) products for cancer and autoimmune disease, presented updated data from the Phase 1 ...
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - Allogene Therapeutics ( NASDAQ:ALLO )
SOUTH SAN FRANCISCO, Calif., May 23, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc. ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ( AlloCAR T™ ) products for cancer and autoimmune disease, today announced that it will participate in four ...
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel - Allogene Therapeutics ( NASDAQ:ALLO )
SOUTH SAN FRANCISCO, Calif., May 22, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc.
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
SOUTH SAN FRANCISCO, Calif., May 22, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc. ( Nasdaq: ALLO ) , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ( AlloCAR T™ ) products for cancer and autoimmune disease, today announced the publication of two ...
REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research
Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. The transaction is expected to close by third-quarter 2025.
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus
KOD reports a wider-than-expected loss for the first quarter of 2025. The company provides updates regarding its pipeline development plans.
Allogene Therapeutics ( ALLO ) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Allogene Therapeutics (ALLO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the ...
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus
FATE incurs a narrower-than-expected loss in the first quarter. The company's innovative pipeline remains in focus.
EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line
Exelixis' first-quarter earnings and sales beat estimates as lead drug Cabometyx maintains momentum. The company raises its sales guidance for 2025.
Allogene's Q1 Earnings In Line With Estimates, Sales Nil
ALLO's first-quarter earnings match estimates. Devoid of marketed products, the company records nil sales in the quarter.
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus
XENE incurs narrower-than-estimated first-quarter 2025 loss. Studies on lead candidate, azetukalner, in epilepsy and MDD are progressing well.
Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y
EDIT announces encouraging first-quarter 2025 results, as both earnings and revenues beat estimates.
RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up
Dr. Reddy's stock is up on encouraging fiscal fourth-quarter 2025 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update - Allogene Therapeutics ( NASDAQ:ALLO )
Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc.
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology ( ASCO ) Annual Meeting - Allogene Therapeutics ( NASDAQ:ALLO )
SOUTH SAN FRANCISCO, Calif., April 23, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc.
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology ( ASCO ) Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 23, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc. ( Nasdaq: ALLO ) , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ( AlloCAR T™ ) products for cancer and autoimmune disease, today announced that it will present ...
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug
The FDA's fast track designations will facilitate rapid development and expedited review of ALLO's autoimmune disease candidate.
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil
ALLO's fourth-quarter earnings beat estimates. Devoid of marketed products, the company records no sales in the quarter.
Adherex Technologies Inc. ( FENC ) Reports Q4 Loss, Misses Revenue Estimates
Adherex Technologies (FENC) delivered earnings and revenue surprises of -110.71% and 73.17%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
SOUTH SAN FRANCISCO, Calif., March 03, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc. ( Nasdaq: ALLO ) , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ( AlloCAR T™ ) products for cancer and autoimmune disease, today announced that it will report ...
Rhythm Pharmaceuticals, Inc. ( RYTM ) Reports Q4 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -4.35% and 2.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc. ( Nasdaq: ALLO ) , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ( AlloCAR T™ ) products for cancer and autoimmune disease, today announced an expanded strategic ...
